News | Thrombectomy Devices | May 21, 2018

Medtronic MindFrame Capture LP Revascularization Device Recalled

FDA warns of risk of delivery wire breaking or separating during use, which could cause device to be left in patient’s bloodstream

Medtronic MindFrame Capture LP Revascularization Device Recalled.

May 21, 2018 — Medtronic and the U.S. Food and Drug Administration (FDA) announced a Class I Urgent Medical Device Recall of the MindFrame Capture LP revascularization device on account of a risk of the delivery wire breaking or separating during use. The FDA said the clot retriever could be left inside the patient’s bloodstream, and this or the attempts made to retrieve the device, can lead to further complications; these complications include bleeding, additional blockage of blood vessels, more severe stroke symptoms or death.

On April 4, 2018, Medtronic followed up with their customers with another Urgent Medical Device Recall notice regarding patient management. The notice recommended healthcare providers to:

  • Review the notification and distribute the information to all appropriate personnel;
  • Follow up with the patient closely;
  • Consider antiplatelet therapy;
  • Consider repeating imaging on the patient; and
  • Complete and return the acknowledgement and receipt form to Medtronic.

The MindFrame Capture LP revascularization device is intended to restore blood flow or remove blood clots within a blood vessel in the brain during an acute ischemic stroke in patients who are ineligible for or fail intravenous tissue plasminogen activator (IV t-PA) therapy.

The total number of devices recalled in the U.S. has reached 529, according to the FDA. Product lot numbers affected by the recall are as follows: 300010, 300011, 300012, 300013, 300014, 300015, 300016, 300017 and 300018. Affected devices were manufactured between Feb. 3, 2016, and Jan. 14, 2018; they were distributed between March 18, 2016 and Jan. 17, 2018.

Customers with questions may contact Medtronic Quality Assurance by email at [email protected] or by phone at 1(800) 633-8766.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report online: www.fda.gov/MedWatch/report
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

For more information: www.medtronic.com, www.fda.gov

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...